Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Leishen Energy Holding Co., Ltd. - Ordinary Shares
(NQ:
LSE
)
5.310
-0.500 (-8.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 27, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Leishen Energy Holding Co., Ltd. - Ordinary Shares
< Previous
1
2
3
Next >
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
March 20, 2025
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
March 19, 2025
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Stay updated with the stocks that are on the move in today's after-hours session.
March 19, 2025
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via
Chartmill
Nasdaq Gains Over 1%; Williams-Sonoma Shares Plunge After Q4 Results
March 19, 2025
Via
Benzinga
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
March 19, 2025
65% oncology products revenue growth drove profitable operation and supported new ATTC platform
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
March 19, 2025
Via
Benzinga
Nexxen Expands U.S. Partnership with Tubi to U.K.
March 19, 2025
Strategic partnership enhances advertiser engagement and monetisation in the growing U.K. streaming market
From
Nexxen International Ltd.
Via
GlobeNewswire
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
March 18, 2025
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Executive Appointments Strengthen Nexxen’s Data, Streaming and Omnichannel Expertise
March 13, 2025
Strategic leadership hires enhance the company’s U.S. regional and global growth as well as its commitment to clients
From
Nexxen International Ltd.
Via
GlobeNewswire
Caledonia Mining Corporation Plc: Notice of Results and Investor Presentation
March 11, 2025
From
Caledonia Mining Corporation Plc
Via
GlobeNewswire
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
March 10, 2025
From
AVACTA GROUP PLC
Via
GlobeNewswire
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts
March 07, 2025
Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments
From
AVACTA GROUP PLC
Via
GlobeNewswire
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
March 06, 2025
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
March 05, 2025
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED to Announce 2024 Final Results
February 19, 2025
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Caledonia Mining Corporation Plc: Appointment of New Chief Financial Officer
February 19, 2025
From
Caledonia Mining Corporation Plc
Via
GlobeNewswire
Leishen Energy Holding Co., Ltd. Announces Fiscal Year 2024 Financial Results Highlighting Strong Operating Cash Flow and Stable Gross Margins
February 18, 2025
From
Leishen Energy Holding Co., Ltd.
Via
GlobeNewswire
Caledonia Mining Corporation Plc: Appointments of Stefan Buys and Lesley Goldwasser as Non-Executive Directors
February 14, 2025
From
Caledonia Mining Corporation Plc
Via
GlobeNewswire
Metals & Mining Virtual Investor Conference Agenda Announced for February 12th and 13th
February 10, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
January 30, 2025
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Nexxen Fuels Growth with Live Sports Offerings and Key Partnerships, Reaching Highly Engaged Audiences Across Channels
January 28, 2025
By collaborating with publisher partners and DSPs, Nexxen saw an increase in spend on live sports packages, including a 315% increase from StackAdapt campaigns
From
Nexxen International Ltd.
Via
GlobeNewswire
Caledonia Mining Corporation Plc: Blanket Mine Q4 and FY 2024 Production and 2025 Guidance
January 14, 2025
Blanket production meets guidance; continued investment in growth and efficiency
From
Caledonia Mining Corporation Plc
Via
GlobeNewswire
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
January 13, 2025
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
January 07, 2025
From
HOOKIPA Pharma Inc.
Via
GlobeNewswire
Nexxen Launches Nexxen U, a First-of-its-Kind Education Program for Linear, Connected TV and Digital Convergence
January 06, 2025
From
Nexxen International Ltd.
Via
GlobeNewswire
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
January 01, 2025
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
January 01, 2025
From
HUTCHMED (China) Limited
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.